581 related articles for article (PubMed ID: 31813004)
21. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
[TBL] [Abstract][Full Text] [Related]
22. Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.
Zhou S; Xie J; Huang Z; Deng L; Wu L; Yu J; Meng X
Cancer Lett; 2021 Apr; 502():166-179. PubMed ID: 33450361
[TBL] [Abstract][Full Text] [Related]
23. Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.
Leonardi GC; Gainor JF; Altan M; Kravets S; Dahlberg SE; Gedmintas L; Azimi R; Rizvi H; Riess JW; Hellmann MD; Awad MM
J Clin Oncol; 2018 Jul; 36(19):1905-1912. PubMed ID: 29746230
[TBL] [Abstract][Full Text] [Related]
24. There and back again: An immunotherapy tale.
Guo Y; Krupnick AS
J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610
[No Abstract] [Full Text] [Related]
25. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
26. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
Chen Y; Gao M; Huang Z; Yu J; Meng X
J Hematol Oncol; 2020 Jul; 13(1):105. PubMed ID: 32723363
[TBL] [Abstract][Full Text] [Related]
27. First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors.
Bylicki O; Barazzutti H; Paleiron N; Margery J; Assié JB; Chouaïd C
BioDrugs; 2019 Apr; 33(2):159-171. PubMed ID: 30825132
[TBL] [Abstract][Full Text] [Related]
28. [Not Available].
Mignard X; Chaabane N; Fallet V; Wislez M
Bull Cancer; 2018 Dec; 105 Suppl 1():S16-S23. PubMed ID: 30595194
[TBL] [Abstract][Full Text] [Related]
29. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
30. The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer.
Xu X; Huang Z; Zheng L; Fan Y
Int J Cancer; 2018 Jun; 142(11):2344-2354. PubMed ID: 29318609
[TBL] [Abstract][Full Text] [Related]
31. Hypofractionated radiation therapy with versus without immune checkpoint inhibitors in patients with brain metastases: A meta-analysis.
Yang L; Liu L; Wu X; Guo X; Yang Y; Wang T
Int Immunopharmacol; 2020 Mar; 80():106148. PubMed ID: 31978802
[TBL] [Abstract][Full Text] [Related]
32. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
[TBL] [Abstract][Full Text] [Related]
33. Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment.
Berghoff AS; Venur VA; Preusser M; Ahluwalia MS
Am Soc Clin Oncol Educ Book; 2016; 35():e116-22. PubMed ID: 27249713
[TBL] [Abstract][Full Text] [Related]
34. Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy.
Hwang WL; Niemierko A; Hwang KL; Hubbeling H; Schapira E; Gainor JF; Keane FK
JAMA Oncol; 2018 Feb; 4(2):253-255. PubMed ID: 28973343
[TBL] [Abstract][Full Text] [Related]
35. Current status of immune checkpoint inhibition in early-stage NSCLC.
Vansteenkiste J; Wauters E; Reymen B; Ackermann CJ; Peters S; De Ruysscher D
Ann Oncol; 2019 Aug; 30(8):1244-1253. PubMed ID: 31143921
[TBL] [Abstract][Full Text] [Related]
36. Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors.
Barlesi F; Tomasini P
Lancet Oncol; 2020 May; 21(5):607-608. PubMed ID: 32251624
[No Abstract] [Full Text] [Related]
37. Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis.
Chen H; Feng Y; Zhou Y; Tao Y; Tang L; Shi Y
Cancer Immunol Immunother; 2022 Dec; 71(12):3071-3085. PubMed ID: 35648238
[TBL] [Abstract][Full Text] [Related]
38. The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials.
Lin GF; Xu Y; Lin H; Yang DY; Chen L; Huang LL; Su XS; Xu YX; Zeng YM
Int Immunopharmacol; 2021 Oct; 99():108011. PubMed ID: 34426108
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.
Kim JH; Kim HS; Kim BJ
Oncotarget; 2017 Jul; 8(29):48248-48252. PubMed ID: 28525386
[TBL] [Abstract][Full Text] [Related]
40. KEYNOTE-024: Unlocking a pathway to lung cancer cure?
Rusch VW; Chaft J; Hellmann M
J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1777-1780. PubMed ID: 29395215
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
